60312-83-6

Basic information

• Product Name: 2-(3-BROMOPHENYL)-ACETAMIDE
• Synonyms: 3-BROMOPHENYLACETAMIDE;2-(3-BROMOPHENYL)-ACETAMIDE;Benzeneacetamide, 3-bromo-
• CAS NO: 60312-83-6
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 214.06
• Product Categories: Aryl;Organohalides
• Mol File: 60312-83-6.mol

Chemical Properties

• Boiling Point: 376.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.537±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 16.04±0.40(Predicted)
• CAS DataBase Reference: 2-(3-BROMOPHENYL)-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-BROMOPHENYL)-ACETAMIDE(60312-83-6)
• EPA Substance Registry System: 2-(3-BROMOPHENYL)-ACETAMIDE(60312-83-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 60312-83-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
2-(3-BROMOPHENYL)-ACETAMIDE is utilized as a pharmaceutical intermediate for the development of new drugs, particularly targeting pain management and inflammation-related conditions. Its reported anti-inflammatory and analgesic effects position it as a promising candidate for creating novel therapeutic agents.
Used in Chemical Research:
In the realm of chemical research, 2-(3-BROMOPHENYL)-ACETAMIDE serves as a key intermediate in the synthesis of other organic compounds and pharmaceuticals, contributing to the advancement of chemical science and the creation of innovative products.
It is crucial to exercise proper safety precautions when handling and using 2-(3-BROMOPHENYL)-ACETAMIDE, as it may present health risks if not managed correctly.

Upstream product

• 31938-07-5 (3-bromophenyl)acetonitrile 
• 1878-67-7 3-Bromophenylacetic acid 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 

Downstream Products

• 954241-25-9 C₁₃H₁₂BrNO₂S 
• 834861-78-8 2-(3-bromophenyl)ethanethioamide 
• 1024584-25-5 C₂₆H₂₆BrN₃O₄ 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 60312-75-6 5-(3-bromo-phenyl)-1-methyl-1H-pyrimidin-4-one 
• 843646-72-0 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
• 103-81-1 Benzeneacetamide 

Relevant articles and documents

STRAD-BINDING AGENTS AND USES THEREOF

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Manganese-Pincer-Catalyzed Nitrile Hydration, α-Deuteration, and α-Deuterated Amide Formation via Metal Ligand Cooperation

A simple and efficient system for the hydration and α-deuteration of nitriles to form amides, α-deuterated nitriles, and α-deuterated amides catalyzed by a single pincer complex of the earth-abundant manganese capable of metal-ligand cooperation is reported. The reaction is selective and tolerates a wide range of functional groups, giving the corresponding amides in moderate to good yields. Changing the solvent from tert-butanol to toluene and using D2O results in formation of α-deuterated nitriles in high selectivity. Moreover, α-deuterated amides can be obtained in one step directly from nitriles and D2O in THF. Preliminary mechanistic studies suggest the transformations contributing toward activation of the nitriles via a metal-ligand cooperative pathway, generating the manganese ketimido and enamido pincer complexes as the key intermediates for further transformations.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Aryl-indolyl maleimides as inhibitors of CaMKIIδ. Part 1: SAR of the aryl region

A family of aryl-substituted maleimides was prepared and studied for their activity against calmodulin dependant kinase. Inhibitory activities against the enzyme ranged from 34 nM to >20 μM and were dependant upon both the nature of the aryl group and the hydrogen bond donating potential of the maleimide ring. Key interactions with the kinase ATP site and hinge region were found to be consistent with homology modeling predictions.

5-LIPOXYGENASE INHIBITORS

The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to benzofuran and benzothiophene derivatives and compositions containing such compounds for the production of medicaments for the treatment of cancers of the central nervous system as monotherapy or combination with other agents.

Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors

The present invention relates to 5-lipoxygenase inhibitors of formula I. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type 1 diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

Mild oxidative one-carbon homologation of aldehyde to amide

One-carbon homologation of aldehyde into amide is realized in one-pot by its reaction with potassium α-p-methoxyphenyl-α-isocyano acetic acid (1c) and hydrochloride salt of dimethylamine (3a) in toluene at room temperature followed by acidic workup. In this multicomponent reaction, 1c served as donor of the CONH2 function to aldehyde, while the dimethylamine acted as a shuttle molecule to initiate/terminate the sequence and to mediate the internal redox process of one of the three-component adducts. Ready accessibility, nominal cost of the reagents, and mild conditions are attractive features of the present method. Copyright

BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS

The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.